Replies to post #970 on Lineage Cell Therapeutics Inc (LCTX)

[Cincinnatus]

AgeX sold at $2.50 a share.

We now seem to have Jim Mellon's stamp of approval and access to TWO Artificial Intelligence platforms to hopefully expedite and provide more efficacy to our research process.

There's abundant evidence of poor human decision making in the biotech world that I'm inclined to approve of the addition of machine intelligence decision making to the AgeX process.